CAMBRIDGE, England--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration with 54gene, a health technology company whose mission is to advance precision medicine capabilities in Africa through research, advanced molecular diagnostics and clinical programs. The partnership will support the establishment of a new genetics facility in Lagos, Nigeria, equipped with a suite of Illumina's cutting-edge sequencing and high-density microarray technology platforms, which will generate genetic information for health research and drug development.

Africa contains more genetic diversity than any other continent because the African genome is the oldest human genome. Yet it is estimated that fewer than 3% of the genomes analyzed come from Africans, making it a potentially rich source of new genetic information for health and drug discovery research, which 54gene intends to leverage as a global research resource while ensuring Africans benefit from cutting-edge medical innovations.

Paula Dowdy, SVP, General Manager EMEA, Illumina, said, Its incredibly important to ensure equitable access to genomic sequencing technology across the world so that genomes can be interpreted in the context of global diversity. Through partnerships such as this with 54gene, we aim to remove barriers of access to sequencing and expand the benefits of genomics to as many people as possible.

54gene Founder and CEO Dr. Abasi Ene-Obong said, The addition of Illuminas cutting-edge technology to our research and diagnostic capabilities is a critical step for 54gene in fulfilling our mission of equalizing access to precision medicine. This is part of our wider commitment to build capacity and infrastructure in Africa, which will allow us to significantly expand genomics research, while also improving health outcomes on the continent. Alongside our many partners in the African medical and scientific community, we want to make advanced molecular diagnostics more accessible to the region, while creating hundreds of skilled jobs in molecular biology and bioinformatics.

Through the partnership, African samples stored in 54genes de-identified biobank, will be genotyped, sequenced and analyzed without the need to send samples overseas, reflecting Illuminas commitment to enabling Africa to expand its genomic capabilities. Having local infrastructure will reduce costs and turnaround time for test results. Illumina will also deliver its renowned training to support the use of its sequencing and microarray equipment and ensure ongoing support for 54genes growing team of molecular scientists.

###

To learn more, visit the Illumina News Center.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit http://www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

About 54gene

54gene is a health technology company advancing the state of healthcare through large-scale discovery and translational research, advanced molecular diagnostics, and inclusive clinical programs for the benefit of Africans and the global population. Founded in 2019, 54gene utilizes human genetic data derived from diverse African populations, to improve the development, availability, and efficacy of medical products and diagnostics that will prove beneficial to Africans and the wider global population.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are our ability to expand the adoption and use of genomics, especially in clinical settings, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts expectations, or to provide interim reports or updates on the progress of the current quarter.

View original post here:

Illumina Collaborates With 54gene in the Creation of a World-Class Genomics Facility in Nigeria - Business Wire